Clinical Trials Logo

Relapsed Neuroblastoma clinical trials

View clinical trials related to Relapsed Neuroblastoma.

Filter by:

NCT ID: NCT01850888 Suspended - Clinical trials for Relapsed Neuroblastoma

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Start date: December 2013
Phase: N/A
Study type: Interventional

This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

NCT ID: NCT01109238 Completed - Clinical trials for Refractory Neuroblastoma

A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma

Start date: April 2010
Phase:
Study type: Observational

The investigators are studying new ways to make treatment decisions for these types of cancer. Technologies at the Van Andel Research Institute (VARI) are available to determine a tumor's molecular makeup (gene expression profile). This technology (called "Xenobase") is being used to discover new ways to understand cancers and potentially predict the best treatments for patients with cancer. The researchers at VARI have filed a patent on the Xenobase and the specific network analysis method that the investigators will be using as part of this study. A specimen obtained from the tumor during a recent surgical, biopsy, or bone marrow procedure will be sent to the Van Andel Research Institute. Researchers will attempt to identify the molecular makeup within the specimen, as well as in blood and urine samples in patients with aggressive and/or refractory cancer. This additional testing is different than the routine tests currently performed at the hospital for the evaluation of cancer. The goals of this part of the study are: To determine if the investigators tumor board committee (at minimum a panel of 3 oncologists and 1 pharmacist) can use patient specific cancer cells to make real-time treatment decision using patient specific genetic information, and predicted therapies generated in the Xenobase report.